Aurinia Pharmaceuticals I... (AUPH)

Things are heating up in the biotechnology space, with a flurry of recent initial public offerings and some notable insider purchases of the past week or so.

On Thursday, Aurinia Pharmaceuticals Inc AUPH reported fourth-quarter earnings of 1 cent per share, compared to a loss of 19 cents a year ago and the consensus loss of 2 cents.

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH ) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Andrea Christopher - Head, Corporate Communications and Investor Relation...

Aurinia Pharmaceuticals (AUPH) came out with quarterly earnings of $0.09 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to loss of $0.19 per share a year ago.

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Reports Financial Results for the Three and Twelve Months Ended December 31, 2024 and Provides Update on Recent Corporate Progress.

AUPH's Lupkynis showed modest revenue growth from Q2'24 to Q3'24, but limited sales growth going from Q2 to Q3 has been seen previously. Full-year 2024 net product revenue guidance of $210M-$220M appe...

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals to Release 2024 Fourth Quarter and Full Year Financial and Operational Results on February 27, 2025.

Aurinia (AUPH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Small biotech stocks have struggled recently, with the SPDR® S&P Biotech ETF down over 15% in the past ten weeks. The pullback has presented significantly lower entry points on myriad small and mid-ca...